Merck to Significantly Increase HPV Vaccine Supply to China in 2022

On January 11, according to Caixin, MSD stated that the company's HPV vaccine supply to China has been increasing year by year and will significantly increase in 2022. Cervical cancer is currently the most likely cancer to be eliminated at the public health level through comprehensive HPV prevention and control measures, and the demand for HPV vaccines among the Chinese public has been strong in recent years. It was revealed that MSD is also actively conducting clinical trials to expand the indications of the HPV vaccine, aiming to cover more age groups and populations to protect the health of more people in China.